Stock Scorecard



Stock Summary for Autolus Therapeutics plc (AUTL) - $1.35 as of 5/12/2025 7:53:26 PM EST

Total Score

10 out of 30

Safety Score

36 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for AUTL

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for AUTL

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for AUTL

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for AUTL

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for AUTL (36 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 8
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for AUTL

Autolus Therapeutics Announces License of AUCATZYL® ( obecabtagene autoleucel ) Issued by UK MHRA for Adult Patients ( ≥ 18 years ) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia ( R/R B-ALL ) ( 1 ) 4/25/2025 4:06:00 PM
Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event - Autolus Therapeutics ( NASDAQ:AUTL ) 4/23/2025 8:05:00 PM
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Autolus Therapeutics ( NASDAQ:AUTL ) 4/22/2025 11:00:00 AM
Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 4/22/2025 11:00:00 AM
Remix Therapeutics Appoints Linda C. Bain to Board of Directors 4/15/2025 11:00:00 AM
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - Autolus Therapeutics ( NASDAQ:AUTL ) 4/2/2025 11:00:00 AM
Autolus Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference 4/2/2025 11:00:00 AM
Autolus Therapeutics to Host R&D Investor Event on Wednesday, April 23, 2025 4/1/2025 11:00:00 AM
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 - Autolus Therapeutics ( NASDAQ:AUTL ) 3/6/2025 12:00:00 PM
Autolus Therapeutics to Report Fourth Quarter 2024 Financial Results and Host Conference Call on March 20, 2025 3/6/2025 12:00:00 PM

Financial Details for AUTL

Company Overview

Ticker AUTL
Company Name Autolus Therapeutics plc
Country USA
Description Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United Kingdom.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 12/31/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 1.35
Price 4 Years Ago 5.19
Last Day Price Updated 5/12/2025 7:53:26 PM EST
Last Day Volume 2,763,833
Average Daily Volume 2,392,031
52-Week High 1.48
52-Week Low 1.15
Last Price to 52 Week Low 17.39%

Valuation Measures

Trailing PE N/A
Industry PE 71.47
Sector PE 47.92
5-Year Average PE -3.56
Free Cash Flow Ratio 1.59
Industry Free Cash Flow Ratio 17.21
Sector Free Cash Flow Ratio 30.82
Current Ratio Most Recent Quarter 10.88
Total Cash Per Share 0.85
Book Value Per Share Most Recent Quarter 1.61
Price to Book Ratio 0.77
Industry Price to Book Ratio 9.53
Sector Price to Book Ratio 27.83
Price to Sales Ratio Twelve Trailing Months 34.71
Industry Price to Sales Ratio Twelve Trailing Months 47.14
Sector Price to Sales Ratio Twelve Trailing Months 25.47
Analyst Buy Ratings 8
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 266,129,000
Market Capitalization 359,274,150
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -5.89%
Reported EPS 12 Trailing Months -0.86
Reported EPS Past Year -0.26
Reported EPS Prior Year -0.86
Net Income Twelve Trailing Months -220,662,000
Net Income Past Year -220,662,000
Net Income Prior Year -208,383,000
Quarterly Revenue Growth YOY 681.00%
5-Year Revenue Growth 28.33%
Operating Margin Twelve Trailing Months -261,600.00%

Balance Sheet

Total Cash Most Recent Quarter 227,380,000
Total Cash Past Year 227,380,000
Total Cash Prior Year 239,566,000
Net Cash Position Most Recent Quarter 227,380,000
Net Cash Position Past Year 227,380,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 427,325,000
Total Stockholder Equity Prior Year 111,474,000
Total Stockholder Equity Most Recent Quarter 427,325,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -241,090,000
Free Cash Flow Per Share Twelve Trailing Months -0.91
Free Cash Flow Past Year -241,090,000
Free Cash Flow Prior Year -156,573,000

Options

Put/Call Ratio 4.17
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.06
MACD Signal -0.07
20-Day Bollinger Lower Band 0.99
20-Day Bollinger Middle Band 1.82
20-Day Bollinger Upper Band 2.64
Beta 1.76
RSI 46.78
50-Day SMA 3.03
150-Day SMA 3.25
200-Day SMA 3.66

System

Modified 5/12/2025 6:10:47 PM EST